Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telavancin
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With Subarachnoid Hemorrhage
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : Telavancin
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telavancin
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2017
Lead Product(s) : Telavancin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telavancin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Theravance Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Telavancin in Normal and Obese Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2016
Lead Product(s) : Telavancin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Theravance Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telavancin
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Theravance Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2015
Lead Product(s) : Telavancin
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Theravance Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2014
Lead Product(s) : Telavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2013
Lead Product(s) : Telavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Theravance Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2011
Lead Product(s) : Telavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Theravance Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telavancin
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2010
Lead Product(s) : Telavancin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable